Get started
Author

Yuichi Sakamori

Observed names: Sakamori, Yuichi, Y. Sakamori, YUICHI SAKAMORI
ORCID: 0000-0001-6421-7266
Observed ORCID: 0000-0001-6421-7266
OpenAlex ID: A5045527646
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
2012 · Yosuke Togashi, Katsuhiro Masago, et al. · Cancer Chemotherapy and Pharmacology · 287
PDF
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
2019 · Ichiro Yamauchi, Akihiro Yasoda, et al. · PLoS ONE · 141
PDF
Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer
2010 · Yosuke Togashi, Katsuhiro Masago, et al. · Journal of Thoracic Oncology · 135
PDF
Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients
2017 · Takashi Nomizo, Hiroaki Ozasa, et al. · Scientific Reports · 111
PDF
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study
2025 · Jeffrey D. Bradley, Shunichi Sugawara, et al. · Journal of Clinical Oncology · 97
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy
2019 · Ryusuke Hatae, Kenji Chamoto, et al. · JCI Insight · 92
PDF
Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
2011 · Yosuke Togashi, Katsuhiro Masago, et al. · Cancer Chemotherapy and Pharmacology · 80
PDF
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
2020 · Takahiro Tsuji, Hiroaki Ozasa, et al. · Nature Communications · 79
PDF
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma
2010 · Yosuke Togashi, Katsuhiro Masago, et al. · Cancer · 67
PDF
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade
2024 · Hidetoshi Hayashi, Kenji Chamoto, et al. · Journal of Clinical Investigation · 61
Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis
2010 · Yosuke Togashi, Katsuhiro Masago, et al. · Journal of Thoracic Oncology · 57
PDF
MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression
2020 · Yuto Yasuda, Hiroaki Ozasa, et al. · Cell Death and Disease · 51
PDF
Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model
2018 · Takahiro Tsuji, Hiroaki Ozasa, et al. · Molecular Cancer Research · 49
PDF
Prognostic Significance of Preexisting Interstitial Lung Disease in Japanese Patients With Small-Cell Lung Cancer
2011 · Yosuke Togashi, Katsuhiro Masago, et al. · Clinical Lung Cancer · 46
PDF
Combination bezafibrate and nivolumab treatment of patients with advanced non–small cell lung cancer
2022 · Kentaro Tanaka, Kenji Chamoto, et al. · Science Translational Medicine · 43
Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
2013 · Yuka Kuriyama, Young Hak Kim, et al. · Case Reports in Oncology · 43
Comprehensive genomic profiling for patients with chemotherapy‐naïve advanced cancer
2020 · Tomohiro Kondo, Junichi Matsubara, et al. · Cancer Science · 41
PDF
Nivolumab in non-small-cell lung cancer with EGFR mutation
2017 · H. Yoshida, Y.H. Kim, et al. · Annals of Oncology · 39
High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib
2013 · Young Hak Kim, Hiroaki Ozasa, et al. · Journal of Thoracic Oncology · 39
Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer
2021 · Hitomi Ajimizu, Hiroaki Ozasa, et al. · Scientific Reports · 32
PDF
Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer
2011 · Yosuke Togashi, Katsuhiro Masago, et al. · Lung Cancer · 31
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature
2012 · Yosuke Togashi, Katsuhiro Masago, et al. · Lung Cancer · 30
PDF
Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients With Non–Small-Cell Lung Cancer With Pleural Effusion
2011 · Katsuhiro Masago, Yosuke Togashi, et al. · Clinical Lung Cancer · 23
Two Cases of Cancer-associated Retinopathy Combined with Small-cell Lung Cancer
2011 · Yuichi Sakamori, Young Hak Kim, et al. · Japanese Journal of Clinical Oncology · 22
Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib
2010 · Katsuhiro Masago, Shiro Fujita, et al. · Oncology · 22
Works count: 211
Citation count: 2,208
H-index: 23
I10-index: 45
Year
Topic
Type